ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) went up by 36.52% from its latest closing price compared to the recent 1-year high of $33.34. The company’s stock price has collected 0.54% of gains in the last five trading sessions. Press Release reported 2 hours ago that ImmunoPrecise’s PolyTope(TM) TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays
Is It Worth Investing in ImmunoPrecise Antibodies Ltd. (NASDAQ :IPA) Right Now?
Opinions of the stock are interesting as 0 analysts out of 1 who provided ratings for ImmunoPrecise Antibodies Ltd. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $22.00. IPA currently public float of 17.07M and currently shorts hold a 0.79% ratio of that float. Today, the average trading volume of IPA was 51.82K shares.
IPA’s Market Performance
IPA stocks went up by 0.54% for the week, with a monthly drop of -13.06% and a quarterly performance of -42.90%, while its annual performance rate touched 15.98%. The volatility ratio for the week stands at 5.11% while the volatility levels for the past 30 days are set at 5.52% for ImmunoPrecise Antibodies Ltd.. The simple moving average for the period of the last 20 days is 30.57% for IPA stocks with a simple moving average of -24.23% for the last 200 days.
IPA Trading at 12.95% from the 50-Day Moving Average
After a stumble in the market that brought IPA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.11% of loss for the given period.
Volatility was left at 5.52%, however, over the last 30 days, the volatility rate increased by 5.11%, as shares surge +23.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.73% upper at present.
During the last 5 trading sessions, IPA rose by +45.32%, which changed the moving average for the period of 200-days by -23.81% in comparison to the 20-day moving average, which settled at $5.92. In addition, ImmunoPrecise Antibodies Ltd. saw -62.61% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for IPA
Current profitability levels for the company are sitting at:
- -29.13 for the present operating margin
- -3.92 for the gross margin
The net margin for ImmunoPrecise Antibodies Ltd. stands at -35.19. The total capital return value is set at -20.18, while invested capital returns managed to touch -28.36.
Based on ImmunoPrecise Antibodies Ltd. (IPA), the company’s capital structure generated 29.89 points at debt to equity in total, while total debt to capital is 23.01. Total debt to assets is 16.54, with long-term debt to equity ratio resting at 10.84. Finally, the long-term debt to capital ratio is 8.35.
When we switch over and look at the enterprise to sales, we see a ratio of 3.87, with the company’s debt to enterprise value settled at 0.08. The receivables turnover for the company is 4.93 and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.97.